What does Hemagen Diagnostics, Inc. do?

Hemagen Diagnostics, Inc. (HMGN) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is HMGN's market cap?

Hemagen Diagnostics, Inc. (HMGN) has a market capitalization of approximately $3,100, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does HMGN pay a dividend?

No — Hemagen Diagnostics, Inc. (HMGN) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

HMGN

Hemagen Diagnostics, Inc.

OTC·Biotechnology · Healthcare

$0.00$0.00+0.00%

Market cap$3.10K·Market closed·Aug 25 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−98.40%CAGR −56.29%

Select date range

FromTo

Feb 4, 1993Aug 27, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

HMGN does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 27

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

Revenue$4.04M

Net Income−$907.32K

Net Margin−22.4%

Operating Cash Flow−$358.69K

Capital Expenditures$91.04K

Free Cash Flow−$449.72K

Return on Equity—

Return on Invested Capital−3.0%

Net Debt$4.96M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for HMGN and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how HMGN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HMGN and 80,000+ other tickers.

About Hemagen Diagnostics, Inc.

Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas…

CEO: William Hales
Sector: Healthcare
Industry: Biotechnology
Exchange: OTC
Employees: 15
Website: www.hemagen.com

Peers

RegeneRx Biopharmaceuticals, Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About HMGN

What does Hemagen Diagnostics, Inc. do?: Hemagen Diagnostics, Inc. (HMGN) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is HMGN's market cap?: Hemagen Diagnostics, Inc. (HMGN) has a market capitalization of approximately $3,100, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does HMGN pay a dividend?: No — Hemagen Diagnostics, Inc. (HMGN) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.